Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Barrier Seeks Development Partner For Its Liarozole Treatment In Lamellar Ichthyosis

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase II/III trial fails to meet primary endpoint; FDA and EMEA want more clinical trials, firm tells “The Pink Sheet” DAILY.

You may also be interested in...



Novartis Consumer Health Sales Force To Detail Barrier’s Vusion Ointment

Barrier also moving forward with Phase IV commitments, exec tells “The Pink Sheet” DAILY.

Solvay's Androgel REMS Proposal May Need More Restrictions - Cmte.

Solvay may need a more restrictive Risk Evaluation and Mitigation Strategy for AndroGel 1% to adequately warn against the danger of secondary transfer of the testosterone gel, according to some members of FDA's Pediatric Advisory Committee

FDA Complete Response Slows Down, But Won't Stop, Lundbeck's Serdolect

Agency comes to same conclusion as advisory committee: the risky schizophrenia drug could get approved if an appropriate patient group is identified.

Topics

UsernamePublicRestriction

Register

PS066178

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel